Dulguerov P, Calcaterra T
Department of Surgery, UCLA Medical Center 90024.
Laryngoscope. 1992 Aug;102(8):843-9. doi: 10.1288/00005537-199208000-00001.
A retrospective review was conducted of all esthesioneuroblastoma cases treated at UCLA Medical Center from 1970 through 1990. Patients were staged according to the staging systems of Kadish, et al., Biller, et al., and a new staging system proposed by the authors. Of 26 patients treated, 74% were alive at 5 years and 60% were alive at 10 years. Combined treatment with surgery and radiation is advocated since a recurrence-free status was achieved in 92% of the patients, compared with 14% for surgery alone and 40% for radiation alone. A craniofacial resection was performed in 7 patients, all of whom have remained disease free. Negative prognostic factors included: age over 50 years at presentation, female sex, tumor recurrence, and metastasis. The proposed new staging system predicted disease-free status better than the other staging systems.
对1970年至1990年在加州大学洛杉矶分校医疗中心接受治疗的所有嗅神经母细胞瘤病例进行了回顾性研究。根据卡迪什等人、比勒等人的分期系统以及作者提出的新分期系统对患者进行分期。在接受治疗的26例患者中，74%在5年时存活，60%在10年时存活。提倡手术与放疗联合治疗，因为92%的患者实现了无复发生存，相比之下，单纯手术的患者为14%，单纯放疗的患者为40%。7例患者接受了颅面切除术，所有患者均无疾病复发。不良预后因素包括：就诊时年龄超过50岁、女性、肿瘤复发和转移。所提出的新分期系统比其他分期系统能更好地预测无疾病状态。
